CHT105 injection for relapsed or refractory immune thrombocytopenia
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This study tests an investigational drug called CHT105, given as an injection, for people with immune thrombocytopenia (ITP) that has not responded to or has come back after prior treatments. The goal is to see if it can help improve platelet counts and manage the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have been diagnosed with refractory or relapsed immune thrombocytopenia (ITP).
- Your platelet count has been below 50,000 on at least two separate occasions.
- You have tried at least one prior ITP treatment (such as steroids, immunoglobulins, or rituximab).
- Your blood tests show a certain marker (CD19/CD70) on your B cells.
- Your major organs (like bone marrow, liver, kidneys) are functioning within acceptable ranges.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immunotherapy called CAR-T cells that target two proteins (CD19 and BCMA) on immune cells. It is for adults with severe ITP that has not improved with other treatments. The goal is to reset the immune system to stop attacking platelets.
This trial tests a new drug called CM336 for people with immune thrombocytopenia (ITP) that hasn't responded well to other treatments. It aims to see if CM336 can safely help raise platelet counts and reduce bleeding risk.
This trial tests a combination of two medications—one that targets specific immune cells (CD20 antibody) and one that blocks a key enzyme in those cells (BTK inhibitor)—for people with ITP or AIHA that hasn't improved after standard treatments. The goal is to see if this combination can help control the disease and reduce symptoms.
This trial tests a new type of cell therapy (CAR T cells) that targets and removes specific immune cells causing low platelets. It is for people with immune thrombocytopenia (ITP) that has not improved with standard treatments. The goal is to see if this therapy is safe and can help raise platelet counts.
This trial tests an investigational drug called CID-103 for adults with chronic immune thrombocytopenia (ITP), a condition where the immune system destroys platelets. It aims to find the right dose and see if it can safely increase platelet counts to reduce bleeding risk.
This early-phase trial tests an investigational cell therapy called PRG-1801 for people with immune thrombocytopenia (ITP) that hasn't responded to or has come back after standard treatments. It aims to see if PRG-1801 can safely help raise platelet counts.
Hear when a new Immune Thrombocytopenia (ITP) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.